Humira holds on for another quarter as AbbVie beats expectations

27 July 2018
abbvie_blue_large

Chicago’s AbbVie (NYSE: ABBV) has reported second quarter revenues of $8.3 billion, up 19.2% on the same period last year, ahead of many analysts’ expectations.

Using Generally Accepted Accounting Principles (GAAP), the firm reported an earnings per share figure of $1.26.

The results were supported by continued strong performance for blockbuster anti-TNF therapy Humira (adalimumab), with sales increasing 10% on a reported basis, despite increasing competition from generics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical